Data backs Corgentech pain drug

Shares of Corgentech surged on news that a mid-stage trial produced positive data for 4975, the company's experimental pain therapy. The data demonstrated that patients recovering from knee replacement surgery experienced significantly lower pain scores while taking 4975. Subjects in the 50-patient study were given a combination of either morphine and 4975 or morphine and a placebo.

"4975 has demonstrated its ability to provide relief of acute and chronic pain to patients experiencing post-surgical, neuropathic and musculoskeletal pain for weeks to months after only a single, local administration. Unlike opioids, which have systemic side effects including nausea, vomiting, constipation and respiratory depression, 4975 appears to have a more favorable safety profile," said Daniel J. Gennevois, M.D., vice president of medical affairs at Corgentech.

- here's the AP report on the Corgentech data

Suggested Articles

Out of options, Tocagen will become Forte Biosciences’ route to the public markets through an all-stock reverse merger.

Reich co-founded Effector and served as its SVP of research but has moved on to take up the CSO position at Turning Point Therapeutics.

BioMarin’s hemophilia A drug has been set an Aug. 21 PDUFA date as the California biotech looks to gain a speedy approval.